Next Article in Journal / Special Issue
A High-Performance Liquid Chromatography Assay Method for the Determination of Lidocaine in Human Serum
Previous Article in Journal
Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release
Previous Article in Special Issue
The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessArticle
Pharmaceutics 2017, 9(4), 51; doi:10.3390/pharmaceutics9040051

In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B

ContraVir Pharmaceuticals Inc., Edison, NJ 08837, USA
Author to whom correspondence should be addressed.
Received: 27 August 2017 / Revised: 28 October 2017 / Accepted: 2 November 2017 / Published: 9 November 2017
(This article belongs to the Special Issue Pharmacokinetics and Drug Metabolism in Canada: The Current Landscape)
View Full-Text   |   Download PDF [2624 KB, uploaded 9 November 2017]   |  


The cytochrome P450-mediated Phase I in vitro metabolism of CRV431 was studied using selective chemical inhibition and recombinant human enzymes. Additionally, the metabolic profile of CRV431 in human, rat, and monkey liver microsomes was investigated. Liver microsomes were incubated for 0–80 min with CRV431, and the metabolite profile was assessed by electrospray ionization liquid chromatography mass spectrometry (ESI-LCMS). CRV431 was extensively metabolized through oxidation to produce various hydroxylated and demethylated species. Species identified included monohydroxylated CRV431 (two distinct products), dihydroxylated CRV431, demethylated CRV431 (two distinct products), demethylated and hydroxylated CRV431 (two distinct products), didemethylated and hydroxylated CRV431, and didemethylated and dihydroxylated CRV431. The magnitude of metabolism was greatest in monkey, followed by human, followed by rat. Importantly, all of the species identified in human microsomes were correspondingly identified in monkey and/or rat microsomes. Human liver microsome studies using selective chemical inhibition, as well as studies using recombinant human cytochrome P450 enzymes, revealed that the major enzymes involved are cytochromes P450 3A4 and 3A5. Enzymes 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 are not involved in the in vitro metabolism of CRV431. This information will be useful for the further development of CRV431 both preclinically and clinically. View Full-Text
Keywords: cyclophilin inhibitor; CRV431; P450; metabolism; species differences cyclophilin inhibitor; CRV431; P450; metabolism; species differences

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Trepanier, D.J.; Ure, D.R.; Foster, R.T. In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B. Pharmaceutics 2017, 9, 51.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top